Literature DB >> 7510129

The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages.

G M Wilkins1, D S Leake.   

Abstract

Oxidised low-density lipoprotein (LDL) produced by the action of arterial cells, including macrophages, has been implicated in atherosclerosis. We have investigated the effect of inhibitors of various cellular free-radical generating enzymes on macrophage-mediated LDL oxidation. Xanthine oxidase and nitric oxide synthase are not responsible for LDL modification by resident mouse peritoneal macrophages. Eicosatetraynoic acid, a lipoxygenase inhibitor, produced a dose-dependent irreversible inhibition of macrophage modification of LDL, but at concentrations rather close to those toxic to the cells. Diphenyl and diphenylene iodonium, NADPH oxidase and mitochondrial electron transport inhibitors, inhibited macrophage oxidation of LDL, at concentrations that were not obviously toxic. This suggests that NADPH oxidase, or some other flavin nucleotide-dependent process, may be involved in LDL oxidation by macrophages. Wortmannin and thiopropionic acid dilauryl ester did not inhibit LDL oxidation, suggesting that inhibition of NADPH oxidase may not be the means by which the iodonium compounds inhibit LDL oxidation. Macrophages from C3H/HeJ mice, which lack receptors for lipopolysaccharide, modified LDL normally, suggesting that the inadvertent priming of resident macrophages by traces of lipopolysaccharide bound to LDL was not involved in LDL oxidation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510129     DOI: 10.1016/0005-2760(94)90140-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  The effects of ascorbate and dehydroascorbate on the oxidation of low-density lipoprotein.

Authors:  S E Stait; D S Leake
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

2.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

Authors:  C H MacPhee; K E Moores; H F Boyd; D Dhanak; R J Ife; C A Leach; D S Leake; K J Milliner; R A Patterson; K E Suckling; D G Tew; D M Hickey
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

3.  Production of oxidized lipids during modification of low-density lipoprotein by macrophages or copper.

Authors:  K L Carpenter; G M Wilkins; B Fussell; J A Ballantine; S E Taylor; M J Mitchinson; D S Leake
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

4.  Oxidation of low-density lipoprotein by iron at lysosomal pH: implications for atherosclerosis.

Authors:  Leanne Satchell; David S Leake
Journal:  Biochemistry       Date:  2012-04-25       Impact factor: 3.162

5.  A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s.

Authors:  M V Calabuig-Navarro; K G Jackson; C F Kemp; D S Leake; C M Walden; J A Lovegrove; A M Minihane
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

6.  Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed.

Authors:  Feroz Ahmad; David S Leake
Journal:  Chem Phys Lipids       Date:  2018-03-05       Impact factor: 3.329

7.  Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages.

Authors:  Feroz Ahmad; David S Leake
Journal:  J Lipid Res       Date:  2018-11-05       Impact factor: 5.922

8.  Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice.

Authors:  Yichuan Wen; Feroz Ahmad; Zahra Mohri; Peter D Weinberg; David S Leake
Journal:  Atherosclerosis       Date:  2019-09-26       Impact factor: 5.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.